About the Company
We do not have any company description for Pulmonx Corp at the moment.
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & Apparatus
Employees
236
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Pulmonx Corp
After Plunging 37.5% in 4 Weeks, Here's Why the Trend Might Reverse for Pulmonx (LUNG)
Pulmonx Corporation (LUNG) has been beaten down lately with too much selling pressure. While the stock has lost 37.5% over ...
Pulmonx Corporation Announces First Quarter 2025 Financial ... - Nasdaq
Pulmonx Corporation will release Q1 2025 financial results on April 30, with a conference call scheduled for 1:30 p.m. PT. Pulmonx Corporation announced that it will release its financial results ...
Pulmonx Reports Fourth Quarter and Full Year 2023 Financial Results
REDWOOD CITY, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease ...
Pulmonx Corporation (LUNG) Q4 2023 Earnings Call Transcript
Pulmonx Corporation. (NASDAQ:LUNG) Q4 2023 Earnings Conference Call February 21, 2024 4:30 PM ETCompany ParticipantsLaine Morgan - Investor Relations, ...
Pulmonx Corporation (NASDAQ:LUNG) Q1 2024 Earnings Call Transcript
Pulmonx Corporation beats earnings expectations. Reported EPS is $-0.36, expectations were $-0.43. LUNG isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter ...
Can Pulmonx Corporation (LUNG) Climb 43% to Reach the Level ... - Nasdaq
Shares of Pulmonx Corporation (LUNG) have gained 5.6% over the past four weeks to close the last trading session at $39.62, but there could still be a solid upside left in the stock if short-term ...
Pulmonx sets terms for IPO, which value med-tech company at more than ...
Pulmonx Corp. set terms for its initial public offering, in which the California-based medical technology company that provides treatment for emphysema looks to raise up to $106.7 million.
Pulmonx Corporation (LUNG) Q2 2021 Earnings Call Transcript
Pulmonx Corporation (LUNG 0.29%) Q2 2021 Earnings Call Aug 03, 2021, 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good afternoon.
Pulmonx Corporation (LUNG) CEO Glen French on Q2 2021 Results ...
Pulmonx Corporation (NASDAQ: LUNG) Q2 2021 Earnings Conference Call August 3, 2021 4:30 PM ET Company Participants Brian Johnston - IR, Gilmartin Group Glen French - President and CEO Derrick Sung ...
Similar Companies
Loading the latest forecasts...